- Details
- Cora Sternberg discusses the significant advancement in the treatment of urothelial carcinoma, focusing on enfortumab vedotin (EV) in combination with pembrolizumab. This combination, recently approved in the US as a first-line therapy, has shifted the treatment paradigm, offering a potent alternative to traditional platinum-based therapies. Dr. Sternberg highlights the importance of this developm...
|
- Details
- Leslie Ballas hosts a discussion with Kent Mouw, who shares findings from his team’s publication in European Urology on the preclinical effects of combining enfortumab vedotin and sacituzumab govitecan with radiation in treating advanced bladder cancer. He explains the rationale for exploring these combinations early in disease treatment, supported by promising preclinical results indicating addit...
|
- Details
- Sam Chang hosts Sophia Kamran to discuss her recent research on bladder cancer. The study, titled "Genomic Tumor Correlates of Clinical Outcomes Following Organ-sparing Chemoradiation Therapy for Bladder Cancer," focuses on genomic characterizations that could predict outcomes for bladder preservation strategies. Dr. Kamran details the use of genomic and transcriptomic profiling to guide treatment...
|
- Details
- Rashid Sayyid and Zach Klaassen dissect the EV-302 trial, presenting enfortumab vedotin and pembrolizumab as a first-line treatment for advanced urothelial cancer. This trial, marked by its publication in The New England Journal of Medicine, challenges the four-decade reign of platinum-based chemotherapy, revealing its limitations, particularly a median overall survival of merely 15-16 months. Dr....
|
- Details
- Sam Chang engages with Arlene Siefker-Radtke to explore the transformative impact of erdafitinib in treating advanced and metastatic urothelial cancer. Dr. Siefker-Radtke illuminates the targeted approach of erdafitinib, emphasizing its efficacy in hitting specific genetic alterations, particularly FGFR3/2 mutations, prevalent in 15-20% of metastatic bladder tumors. Highlighting the drug's journey...
|
- Details
- Sam Chang interviews Michiel Van der Heijden about the results of the EV-302 trial, comparing enfortumab vedotin plus pembrolizumab (EVP) against chemotherapy in previously untreated advanced urothelial cancer patients. Dr. Van der Heijden outlines the trial's structure and its remarkable findings, noting the hazard ratios for progression-free and overall survival rates that favor EVP. He delves i...
|
- Details
- Andrea Apolo joins Sam Chang in discussing the AMBASSADOR study, focusing on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma. The study showed improved disease-free survival with pembrolizumab versus observation. However, overall survival data is still maturing. Patients who received pembrolizumab had a median disease-free survival of 29 months versus 14 months for the observation...
|
- Details
- Amanda Nizam presents findings from the UNITE study at GU ASCO 2024, exploring enfortumab vedotin's (EV) efficacy in patients with advanced urothelial carcinoma post-platinum-based chemotherapy and maintenance avelumab. This retrospective analysis, involving 633 patients across 16 US sites, reveals that EV's outcomes are consistent with previous trials, even after maintenance avelumab. Despite exp...
|
- Details
- Shilpa Gupta discusses the challenges and progress of the MAIN-CAV study examining the combination of treatments for urothelial cancer in the U.S., impacted by a platinum drug shortage. Despite setbacks, efforts are underway to increase patient enrollment, with assistance from Canadian colleagues. The conversation with Dr. Sam Chang reveals no safety concerns with the combination of TKI and immuno...
|
- Details
- Guru Sonpavde and Matt Galsky delve into the CheckMate 901 study and its implications for advanced bladder cancer treatment. Dr. Sonpavde outlines the study's design, focusing on comparing gemcitabine cisplatin with and without nivolumab in cisplatin-eligible patients. He highlights the study's backdrop, noting previous trials and the potential immunogenic superiority of cisplatin. Dr. Galsky pres...
|
